PRTC - Karuna reports positive safety data for schizophrenia drug KarXT
2023-11-16 17:03:01 ET
More on Karuna Therapeutics
- Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine
- Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript
- Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia
- Karuna Therapeutics GAAP EPS of -$3.16 misses by $0.40
- Karuna Therapeutics submits NDA for schizophrenia drug
For further details see:
Karuna reports positive safety data for schizophrenia drug KarXT